Navigation Links
ProclaRx to Present on New Bacterial Biofilm Therapies at Biotech Showcase January 11- 13, 2016 in San Francisco
Date:1/5/2016

COLUMBUS, Ohio, Jan. 5, 2016 /PRNewswire/ -- ProclaRx LLC, formerly known as Lattice Biotech LLC, has been selected to speak at the 8th Annual Biotech Showcase on January 11 and the Medtech Showcase, January 12, 2016, regarding their breakthrough medical discovery for treatment of patients with serious bacterial infections.

The Ohio based biotechnology company has developed a technology to break down and destroy biofilms, a physical barrier which protects bacteria and prevents antibiotics and the body's immune system from eradicating chronic infections.

Infections with biofilms are associated with indications as those found in advanced wound care, chronic draining ear infections, and CVID sinusitis. They are highly resistant to antibiotics and have a significant ability to evade normal defenses against bacteria. Recurrent infections and antibiotic resistance is a major clinical and public health problem, with bacterial biofilms implicated in more than 80% of infections.

"The ProclaRx biofilm technology addresses an important unmet medical need that will enable effective treatment for numerous chronic bacterial infections," states Dr. Tom Zupancic, Chief Scientific Officer and co-founder. "Our patented platform technology disrupts the biofilm fortress and enables both the body's immune system and antibiotics to better attack the disease." 

Founded in 2014, ProclaRx has exclusive worldwide rights to develop and commercialize

anti-infective technology from the University of Southern California, Ohio State University and Nationwide Children's Hospital. With $5.5 million invested to-date, they are seeking additional financing and strategic partners. The Biotech Showcase is one of the healthcare industry's largest annual healthcare investor conferences.   

About ProclaRx
ProclaRx is a biotechnology company developing innovative therapeutics for patients suffering from serious bacterial infections. ProclaRx has a breakthrough discovery that inhibits and prevents bacterial biofilms. Lead indications include advanced wound care, secretory otitis media and CVID sinusitis. Visit www.proclarx.com or call 949-302-2165 or e-mail info@proclarx.com.

Contact:  Dr. Joseph D. Kittle, Jr.
CEO, ProclaRx
949-302-2165  


'/>"/>
SOURCE ProclaRx
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
2. Bayer to Present New Data Across Oncology Portfolio at ASCO 2013
3. Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting
4. ASCO 2013: Boehringer Ingelheim to Present Data Across Multiple Cancers, Including Different Treatment Settings for Advanced NSCLC
5. Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
6. Amgen Highlights Data To Be Presented At American Society of Clinical Oncology Annual Meeting
7. AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
8. Asmacure to Present Four Posters on Novel Pulmonary Development Compound ASM-024 at American Thoracic Society 2013 International Conference
9. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
10. AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
11. Amgen To Present At The UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2017)... 2017 Nutriceutical Holdings (NH), parent company of ... and KD Pharma Group have decided to join forces ... Pharma Group. KD Pharma Group will become the largest ... the entire company. "We believe we have ... to growing the NH companies by providing us with ...
(Date:5/29/2017)... TEL AVIV, Israel, May 29, 2017  Cellect Biotechnology ... of innovative technology which enables the functional selection of ... financial results for the first quarter ended March 31 ... pleased with our accomplishments in the first quarter of ... the first quarter, we announced the treatment of the ...
(Date:5/23/2017)... 23, 2017  Leaf Healthcare, recognized for developing ... for pressure ulcer prevention, will unveil its comprehensive ... Critical Care Nurses, National Teaching Institute and Critical ... The Leaf Patient Monitoring System is the first ... environment.  The system seamlessly tracks patient movement throughout ...
Breaking Medicine Technology:
(Date:6/22/2017)... ... ... Despite its pervasiveness, many physicians are unfamiliar with how best to treat ... practice. Now, however, a timely review has been published in the Journal of ... NeuP and educating preclinical scientists on its diagnosis and choice of treatment. , The ...
(Date:6/20/2017)... Murfreesboro, Tennessee (PRWEB) , ... June 20, 2017 ... ... chronic care services, announced today that Claritas Capital, a Nashville-based private equity firm, ... to accelerate our expansion plans for some time, and Claritas Capital offers the ...
(Date:6/20/2017)... ... June 20, 2017 , ... Hayes, Inc., ... a new eBook titled “ 5 Questions to Ask Before Entering the Maze ... the Genetic Test Evaluation (GTE) team, the book explores the various types of ...
(Date:6/20/2017)... ... 20, 2017 , ... AMC Health , the leading provider of proven ... trials market. Similar to its approach in demonstrating positive outcomes in the healthcare market, ... proving the value of eVisits to support virtual studies. , In a ...
(Date:6/20/2017)... ... June 20, 2017 , ... With certifications and experience that puts ... NJ, Drs. Adam and Hal Kimowitz are currently accepting new patients at their practice ... can cause for some patients, which is why they offer the latest in modern ...
Breaking Medicine News(10 mins):